Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Rhea-AI Summary

Eledon Pharmaceuticals (NASDAQ: ELDN) has announced its participation in the upcoming Cantor Global Healthcare Conference. The company's CEO, David-Alexandre C. Gros, M.D., will engage in a fireside chat on Wednesday, September 18, 2024, at 8:35 a.m. ET.

Interested parties can register in advance for the webcast of the fireside chat. For those unable to attend live, a replay of the webcast will be made available on the company's website in the Events section following the session. This presentation at a major healthcare conference provides an opportunity for Eledon to showcase its developments and engage with industry professionals and investors.

News Market Reaction – ELDN

-1.56%

-1.56% Session move

In the trading session that priced this news, ELDN declined 1.56%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET.

To register in advance for the fireside chat webcast, sign up here.

A webcast replay will be accessible following the live session on the Company’s website under Events.

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com

Source: Eledon Pharmaceuticals

FAQ

When is Eledon Pharmaceuticals (ELDN) presenting at the Cantor Global Healthcare Conference?

Eledon Pharmaceuticals (ELDN) is presenting at the Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET.

Who will be representing Eledon Pharmaceuticals (ELDN) at the Cantor Global Healthcare Conference?

David-Alexandre C. Gros, M.D., the Chief Executive Officer of Eledon Pharmaceuticals, will be representing the company in a fireside chat at the conference.

How can I watch Eledon Pharmaceuticals' (ELDN) presentation at the Cantor Global Healthcare Conference?

You can register in advance for the webcast of the fireside chat. A replay will also be available on Eledon Pharmaceuticals' website under the Events section after the live session.

What type of presentation will Eledon Pharmaceuticals (ELDN) give at the Cantor Global Healthcare Conference?

Eledon Pharmaceuticals (ELDN) will participate in a fireside chat format presentation at the Cantor Global Healthcare Conference.